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ABSTRACT
Unwanted side effects of drugs are a burden on pa-
tients and a severe impediment in the development
of new drugs. At the same time, adverse drug reac-
tions (ADRs) recorded during clinical trials are an
important source of human phenotypic data. It is
therefore essential to combine data on drugs, tar-
gets and side effects into a more complete picture
of the therapeutic mechanism of actions of drugs
and the ways in which they cause adverse reactions.
To this end, we have created the SIDER (‘Side Ef-
fect Resource’, http://sideeffects.embl.de) database
of drugs and ADRs. The current release, SIDER 4,
contains data on 1430 drugs, 5880 ADRs and 140 064
drug–ADR pairs, which is an increase of 40% com-
pared to the previous version. For more fine-grained
analyses, we extracted the frequency with which
side effects occur from the package inserts. This in-
formation is available for 39% of drug–ADR pairs,
19% of which can be compared to the frequency un-
der placebo treatment. SIDER furthermore contains
a data set of drug indications, extracted from the
package inserts using Natural Language Processing.
These drug indications are used to reduce the rate of
false positives by identifying medical terms that do
not correspond to ADRs.
INTRODUCTION
Reducing adverse drugs reactions (ADRs) and elucidating
their origin has long been a concern of physicians and re-
searchers within their respective fields of medicine. Within
the last years, an increased availability of public data on
drug targets and ADRs enabled large-scale studies that go
beyond individual fields of medicine to a systems biology or
systems medicine approach. For example, it was shown that
ADRs can be used to predict drug targets (1) and that causal
relations between targets andADRs can be elucidated (2,3).
Data on ADRs are generated in two stages. First, dur-
ing placebo-controlled clinical trials, the occurrence and
frequency of ADRs is recorded. In phase III trials, thou-
sands of patients are carefully monitored, and the ADRs
observed during this phase become listed on the package
inserts. Once the drug is on the market, surveillance contin-
ues (‘phase IV’) and doctors may report ADRs to systems
such as the FDAAdverse Event Reporting System (AERS).
ADRs from such reporting systems are drawn from much
larger numbers of patients; however, they are more subject
to confounding biases and the causality may thus be ques-
tionable. Typically, such ADRs are also added to package
inserts in a separate section on post-marketing experience.
In addition, ADRs are reported in the biomedical literature,
e.g. in animal studies or in pre- or post-clinical trial studies,
and in electronic health records, from where they can be ex-
tracted using text mining (4–6).
TomakeADRs amendable to academic research in a sim-
ple way, we developed SIDER (‘Side Effect Resource’) in
2010 when no such resource was freely available for aca-
demic researchers (7). The first version of SIDER contained
not only drugs and their respective ADRs but also fre-
quency information for both drug and placebo treatment.
Users were able to check for the occurrence of specific ADR
on the SIDER website. Thanks to the availability of down-
loadable files, SIDER has since been used in many stud-
ies, for example to identify metabolic dysregulation as a
cause for ADRs (8), to investigate the effect of essential
proteins on ADRs (9) and to predict drug indications (10).
As a further use case, SIDER has been used as the bench-
marking set for text-miningmethods that extract ADRdata
from the literature (4,11), and other databases have incorpo-
rated data from SIDER. For example, ADReCS combined
SIDER 2 data with an independent annotation effort and
further added an ontology of ADRs that allows grouping
of related ADRs (12). IntSide integrated data from SIDER
2 with drug–target and pathway data to pinpoint causes of
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ADRs (13). Despite no longer being the only freely available
ADR resource, SIDER remains heavily used: on average,
the SIDER 2 data set of ADRs was downloaded 74 times
per month in the past year (unique IP addresses per month,
August 2014 to July 2015).
We present here a new release of the SIDER database
with over 40% more drugs, ADRs and drug–ADR pairs
compared to the previous version and more than 2-fold
as many drug–ADR pairs as the published version (see
Table 1). We ensure a high quality of the extracted enti-
ties by manually annotating names, adding synonymous
names and using an additional Natural Language Process-
ing step. Our text-mining system creates amachine-readable
database and a human-readable website with highlighted
terms at the same time, making it possible for users to
quickly trace the origin of extracted ADRs.
DATA COLLECTION AND QUALITY CONTROL
Drug labels with information for professionals were ob-
tained from national registries and charity organizations.
Structured Product Labels, as provided by the FDA in
XML format, could be parsed directly. Labels that were
only available as PDF were converted to HTML, preserv-
ing tabular data formatting to the extent possible. The initial
conversion from the source documents to PDF removes the
logical structure of the documents such as headings. Con-
verting from PDF to HTML yields documents with differ-
ent styles for normal text and headings, but the actual text
formatting varies between documents. We therefore devel-
oped heuristics to automatically identify section and sub-
section headings from the text formatting in the HTML la-
bels. For example, we search for headings of the ADR and
indications section with different wordings to identify the
text style used to indicate the different sections. We also
maintain a list of section titles that indicate that theADRor
indication section have ended (e.g. ‘Interactions with other
drugs’).
Named entity recognition (NER)
We used a dictionary-based approach to detect mentions
of ADRs, diseases, drugs and proteins in the package in-
serts. Names of chemicals and proteins were taken from the
STITCH 4 and STRING 9.1 databases (14,15). In particu-
lar, users can directly use identifiers from SIDER to iden-
tify drug targets in STITCH 4. In STITCH, stereoisomers
and salt forms are usually merged into a common identifier,
although the user has the option to view the isomers sep-
arately. Likewise, the SIDER download files contain iden-
tifiers both with and without stereochemistry, and links to
PubChem are provided on the web frontend. Starting with
SIDER 4, the major version number of SIDER is linked to
the corresponding STITCH version. That is, once STITCH
5 has been released, we will create SIDER 5 with new chem-
ical identifiers. To create a dictionary of ADR and disease
names, we pooled synonyms from theUnifiedMedical Lan-
guage System (UMLS) Metathesaurus (version 2014AA)
for all terms of the Medical Dictionary for Regulatory Ac-
tivities (MedDRA) (version 16.1). We filtered by semantic
type (Supplementary Table S1) and further manually cre-
ated an exclusion list of concepts with the correct semantic
type that did not refer to ADR, such as ‘HIV positive’ or
‘family history of suicide.’ Similarly, we manually inspected
all names that occurred at least 100 times during NER to
create a list of names to be blocked from the dictionary.
Names from the UMLS Metathesaurus often do not
cover all possible permutations of words or their synonyms.
To expand the dictionary, we created a list of candidate syn-
onyms from frequently interchanged words. For each con-
cept, we pooled the words of all names and added syn-
onymous words. Then we scanned the package inserts for
occurrences of these words. In this way, mentions of the
concept could be detected even when the order of words
had been changed. For example, consider the name ‘blood
pressure decreased’. After adding a synonym, the algorithm
might look for the words ‘blood’, ‘pressure’, ‘decreased’ and
‘lower’. It would therefore find new names like ‘decreased
blood pressure’ and ‘lower blood pressure’. We manually
annotated the most frequently occurring novel names and
added only truly synonymous names to the dictionary.After
completing the dictionaries, entities were recognized using
an NER engine that also accounts for orthographic vari-
ation, specifically case variation and insertion/removal of
hyphens and spaces (16). Sentences in the ADR section that
contain negations (e.g. ‘has not been observed’) or specula-
tion (e.g. ‘is suspected’) were excluded (see Supplementary
Table S2).
By tightly integrating parsing of the labels and entity de-
tection, we were able to produce marked-up HTML ver-
sions of the labels. In these files, all detected mentions of the
ADR terms are highlighted, along with names of chemical
compounds and proteins (Figure 1). In previous versions
of SIDER, highlighting of matches and entity recognition
were independent steps, which meant that in some cases the
source of a detected term was not highlighted in the HTML
version. Users can click on ADR terms to get more infor-
mation from SIDER, and on proteins and compounds for
relevant data from Reflect (17).
Detection of drug indications by natural language processing
After entity recognition, we used the Stanford Dependen-
cies (18) package (version 3.4.1) to extract further infor-
mation from the package inserts, analyzing the content of
the sections on indications and ADRs. This Natural Lan-
guage Processing (NLP) approachmakes it possible to iden-
tify sentence fragments that refer to indications of drugs.
As a pre-processing step, we replaced each entity that had
been recognized in the previous step with an internal identi-
fier. This way, entity names that consisted of multiple words
were collapsed to a single noun, making correct parsing of
the sentences easier. With the preprocessed sentences as in-
put, Stanford Dependencies returns a list of dependencies,
which are triplets consisting of the kind of dependency and
the two connected words (the governor and the dependent).
For example, parsing the sentence ‘DRUGmay be used for
the treatment of INDICATION’ returns this list of depen-
dencies, consisting of seven triplets:
nsubjpass(used-4, DRUG-1)
aux(used-4, may-2)
auxpass(used-4, be-3)
root(ROOT-0, used-4)
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Table 1. Data content of ADR databases
ADReCS 1.2 * SIDER 1 SIDER 2 SIDER 4
Increase between
SIDER 2 and 4
Year of release 2015 2009 2012 2015
Number of drugs 1378 888 996 1430 +44%
Number of ADRs 5984 1450 4192 5880 +40%
Number of drug–ADR pairs
total 134022 62269 99423 140064 +41%
with frequency 50490 25068 42331 54772 +29%
with frequency for placebo 0 3640 6334 10790 +70%
*ADReCS statistics were accessed on July 30, 2015.
Table 2. Comparison of extracted indications and ADRs between SIDER 4 and drugs.com (accessed on February 12, 2015)
Indications
(detected by NLP)
Pre-existing conditions
(detected by NLP)
Indications
(detected by NER) ADRs (filtered set)
Counts within SIDER 4
drugs 1236 826 1329 1430
concepts 1338 809 2583 880
drug–concept pairs 4681 2616 12965 140064
Comparison with drugs.com
common drugs 870 615 915 948
common concepts 439 292 553 480
Number of drug–concept pairs
only in drugs.com 1328 1020 1034 2216
intersection 1010 499 1685 349*
only in SIDER 4 655 434 2111 27797
Overlap
relative to SIDER 4 61% 53% 44% 1.2%
relative to drugs.com 43% 33% 62% 13%
*This intersection should be as low as possible, as it hints at false positives in SIDER, see discussion in text.
det(treatment-7, the-6)
prep for(used-4, treatment-7)
prep of(treatment-7, INDICATION-9)
Analyzing this list of dependencies, we extracted the
triplet ‘DRUG, used treatment, INDICATION’ and used
custom rules to determine that this implies an indication for
the drug (Supplementary Table S3). We used such rules to
detect drug combinations, indications and pre-existing con-
ditions of patients that do not refer to ADRs (e.g. ‘In pa-
tients with X, Y may occur’, see Supplementary Table S4).
Extraction of frequencies
Frequencies of ADRs were extracted from tables and free-
text mentions. In case of tables, the header of the table was
analyzed to find out if the reported frequencies are for drug
or placebo treatment. We used a heuristic to exclude ta-
bles that contain other types of data, such as discontin-
uation frequencies. We also extracted frequency informa-
tion from the text of the labels, searching for lists (e.g. ‘fre-
quent: headache, fatigue’) and for numbers in parentheses
(e.g. ‘headache (12%)’).
Filtering steps
To further reduce the rate of false positives, the following
steps were undertaken. First, we manually inspected the
words found at least 100 times and removed terms that did
not correspond to ADRs or were ambiguous. Next, we used
the extracted indications as a filter on ADR found in the
free text of the ADR section (in contrast to those contained
in tables listing the frequency of ADR). As described above,
potential indications of drugs were detected in two ways: ei-
ther by NER in the indications section, or by NLP (yielding
indications and pre-existing conditions of patients). When
a concept had been found by NER in the ADR section of
a package insert, we discarded it as an ADR if the concept
had been detected (i) by NLP on any package insert of the
same drug or (ii) by NER in the indications section of the
same package insert. In the latter case, filtering only applies
to the same package insert due to a higher rate of false pos-
itive indications for NER compared to NLP shown below.
To estimate the accuracy of the extracted indications, we
matched them against a data set of drug indications derived
from the resource drugs.com. We looked for exactly match-
ing terms and used this external data set only for bench-
marking the final set of indications (see Table 2). Among
the overlapping drug–disease pairs, 61% of those found as
an indication by NLP were also contained in the drugs.com
data set. For those detected as preconditions, the fraction
was 53%. Among terms found by text mining in the indica-
tions section, 44% were also contained in the external data
set.
We also used the drug indication data from drugs.com
to obtain an estimate of the false positive rate of ADR in
SIDER. In the previous paragraph, we quantified the over-
lap between indications in drugs.com and SIDER. Here, we
tested the overlap between indications from drugs.com and
ADR found in SIDER. Thus, matching terms point to an
apparent contradiction that could be explained as a false
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Figure 1. Navigating the SIDER website. Users can search for drugs to get an overview of its ADR (A). Clicking on cells in the table of labels and ADRs
takes the user to a separate page (B) where they can inspect all mentions of the ADR.
positive in either drugs.com or SIDER. Of 140064 drug–
ADR pairs in SIDER, 28343 (20%) could be matched to
drugs and diseases found on drugs.com. Of those 28343
drug–disease pairs, only 349 (1.2%) were listed as drug–
indication pairs on drugs.com, showing that indications are
only very rarely misinterpreted as ADRs.
DATA CONTENT AND AVAILABILITY
SIDER is available at http://sideeffects.embl.de/. The new
release, SIDER 4, represents a large increase in the numbers
of drugs, ADRs, drug–ADR pairs and drug frequency en-
tries compared to previous versions (Table 1, Figure 2). The
homepage allows users to interactively browse the database
and to search for drugs andADRs (Figure 1A). The SIDER
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Figure 2. Data content of SIDER. For SIDER versions 1, 2 and 4 the dis-
tribution of (A) drugs per ADR and (B) ADRs per drug is shown. These
distributions do not follow a power law. Note that the current version of
SIDER is the third release, but is designated SIDER 4 because it is based
on the same set of chemicals as STITCH 4.
website enables users to trace drug–side effect pairs to the
drug labels: users can navigate to the drug’s page and click
on the side effect of interest. On the presented drug label,
all instances of the side effect are marked (Figure 1B). In
this way, users can quickly trace the origin of an extracted
side effect in order to rule out false positives. The complete
data set of side effects and the data set of indications are
available for download from the SIDER website in text for-
mat, including PubChem andMedDRA identifiers. In addi-
tion, we have created a GitHub repository (linked from the
SIDER download page) where users can contribute errors
that they detect in SIDER. In this way, other users can filter
the download files, and the authors can remove the source
of the errors in upcoming versions of SIDER.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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